- Home
- INMD vs AQST Comparison
INMD vs AQST Comparison
Compare INMD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMD | AQST |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 879.2M | 809.3M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | INMD | AQST |
|---|---|---|
| Price | $14.56 | $6.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $17.00 | $10.00 |
| AVG Volume (30 Days) | 566.3K | ★ 2.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.42 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $364,494,000.00 | $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.76 | $52.69 |
| P/E Ratio | $6.57 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.14 | $2.12 |
| 52 Week High | $19.78 | $7.55 |
Technical Indicators
Market Signals| Indicator | INMD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 52.76 |
| Support Level | $14.24 | $5.99 |
| Resistance Level | $14.58 | $6.44 |
| Average True Range (ATR) | 0.25 | 0.32 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 91.41 | 54.73 |
Price Performance
Historical ComparisonAbout INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.